MDT

86.16

-0.5%↓

A

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

A

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

A

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

A

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

A

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

75.33 -1.06

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

75.08

Max

76.93

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+30.5% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

12B

Ankstesnė atidarymo kaina

76.39

Ankstesnė uždarymo kaina

75.33

Naujienos nuotaikos

By Acuity

50%

50%

167 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First-Quarter Net Rose on Strong Demand

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First Quarter Net Rose On Strong Demand

2026-04-15 17:13; UTC

Pagrindinės rinkos jėgos

Tesla Shares Rise on Completion of AI5 Chip Design Process

2026-04-15 23:39; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-15 23:35; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

2026-04-15 22:41; UTC

Uždarbis

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

2026-04-15 22:38; UTC

Uždarbis

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

2026-04-15 22:15; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-15 22:15; UTC

Rinkos pokalbiai

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

2026-04-15 22:14; UTC

Uždarbis

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

2026-04-15 22:12; UTC

Uždarbis

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology Swings to Loss in 1Q>300433.SZ

2026-04-15 22:07; UTC

Uždarbis

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

2026-04-15 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Skild AI Acquires Zebra Technologies' Robotics Automation Business

2026-04-15 21:29; UTC

Karštos akcijos

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

2026-04-15 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2026-04-15 20:30; UTC

Uždarbis

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

2026-04-15 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-15 20:06; UTC

Rinkos pokalbiai

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

2026-04-15 19:46; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

2026-04-15 19:25; UTC

Rinkos pokalbiai

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

2026-04-15 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

2026-04-15 18:58; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

2026-04-15 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

2026-04-15 17:45; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

2026-04-15 16:58; UTC

Uždarbis

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

2026-04-15 16:52; UTC

Uždarbis

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

2026-04-15 16:46; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

2026-04-15 16:37; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

30.5% į viršų

12 mėnesių prognozė

Vidutinis 100.25 USD  30.5%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

12

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

167 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat